{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:13:08Z","timestamp":1787062388077,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T00:00:00Z","timestamp":1603756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Princess Margaret Cancer Centre Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The pathogenesis of medication-related osteonecrosis of the jaw (MRONJ), a morbid condition associated with bisphosphonate administration, has not been fully elucidated. Recent research utilizing a murine model has revealed that the neutrophil becomes dysfunctional following exposure to bisphosphonates. Accordingly, the impairment of neutrophil function could play an important role in the pathogenesis of MRONJ via an infectious mechanism mediated by the\u00a0suppression of the innate immune system. Currently, the existing human data are insufficient to substantiate this theory. To\u00a0investigate, we isolated neutrophils from blood and oral rinse samples from bisphosphonate-na\u00efve patients who were recently diagnosed with multiple myeloma both prior to and one month following their initial infusion of pamidronate, an intravenous bisphosphonate agent. Stimulated blood and oral neutrophil superoxide production and chemotactic capabilities were found to be impaired relative to baseline values. These results suggest that impaired neutrophil function may partially contribute to the aetiology underlying the pathophysiological processes linked to the development of MRONJ. Further, as the functional status of circulating neutrophils was reflected in the oral cavity where sampling can be accomplished in a non-invasive fashion, it is conceivable that neutrophil function could serve as a potential biomarker for MRONJ prognostication.<\/jats:p>","DOI":"10.1038\/s41598-020-75272-6","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T07:03:40Z","timestamp":1603782220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The effect of pamidronate delivery in bisphosphonate-na\u00efve patients on neutrophil chemotaxis and oxidative burst"],"prefix":"10.1038","volume":"10","author":[{"given":"Jeffrey W.","family":"Chadwick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard C.","family":"Tenenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Xiang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Glogauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,27]]},"reference":[{"key":"75272_CR1","first-page":"121","volume":"10","author":"T Ibrahim","year":"2013","unstructured":"Ibrahim, T., Mercatali, L. & Amadori, D. Bone and cancer: The osteoncology. Clin. Cases Miner. Bone Metab. 10, 121\u2013123 (2013).","journal-title":"Clin. Cases Miner. Bone Metab."},{"key":"75272_CR2","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman, G. D. Pathogenesis of myeloma bone disease. Leukemia 23, 435\u2013441 (2009).","journal-title":"Leukemia"},{"key":"75272_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-017-0043-6","volume":"8","author":"P Ravi","year":"2018","unstructured":"Ravi, P. et al. Defining cure in multiple myeloma: a comparative study of outcomes of young individuals with myeloma and curable hematologic malignancies. Blood Cancer J. 8, 1\u20137 (2018).","journal-title":"Blood Cancer J."},{"key":"75272_CR4","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1182\/bloodadvances.2019000524","volume":"4","author":"KK Nishimura","year":"2020","unstructured":"Nishimura, K. K. et al. Long-term outcomes after autologous stem cell transplantation for multiple myeloma. Blood Adv. 4, 422\u2013431 (2020).","journal-title":"Blood Adv."},{"key":"75272_CR5","doi-asserted-by":"crossref","unstructured":"F Macedo et al. Bone metastases: an overview. Oncol. Rev. 11, 43\u201349 (2017)","DOI":"10.4081\/oncol.2017.321"},{"key":"75272_CR6","doi-asserted-by":"publisher","first-page":"6243","DOI":"10.1158\/1078-0432.CCR-06-0931","volume":"12","author":"RE Coleman","year":"2006","unstructured":"Coleman, R. E. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin. Cancer Res. 12, 6243\u20136249 (2006).","journal-title":"Clin. Cancer Res."},{"key":"75272_CR7","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.pharmthera.2015.11.008","volume":"158","author":"HH Van Acker","year":"2016","unstructured":"Van Acker, H. H., Anguille, S., Willemen, Y., Smits, E. L. & Van Tendeloo, V. F. Bisphosphonates for cancer treatment: mechanisms of action and lessons from clinical trials. Pharmacol. Ther. 158, 24\u201340 (2016).","journal-title":"Pharmacol. Ther."},{"key":"75272_CR8","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.bone.2011.01.003","volume":"49","author":"M Pazianas","year":"2011","unstructured":"Pazianas, M. & Abrahamsen, B. Safety of bisphosphonates. Bone 49, 103\u2013110 (2011).","journal-title":"Bone"},{"key":"75272_CR9","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1136\/bmj.a1101","volume":"337","author":"AN Wilkinson","year":"2008","unstructured":"Wilkinson, A. N., Viola, R. & Brundage, M. D. Managing skeletal related events resulting from bone metastases. BMJ 337, 1101\u20131105 (2008).","journal-title":"BMJ"},{"key":"75272_CR10","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero, S. L. et al. American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J. Oral Maxillofac. Surg. 72, 1938\u20131956 (2014).","journal-title":"J. Oral Maxillofac. Surg."},{"key":"75272_CR11","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","volume":"40","author":"S Otto","year":"2012","unstructured":"Otto, S. et al. Bisphosphonate-related osteonecrosis of the jaws\u2014characteristics, risk factors, clinical features, localization and impact on oncological treatment. J. Cranio-Maxillofac. Surg. 40, 303\u2013309 (2012).","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"75272_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.adaj.2017.04.002","volume":"148","author":"M El-Rabbany","year":"2017","unstructured":"El-Rabbany, M., Sgro, A., Lam, D. K., Shah, P. S. & Azarpazhooh, A. Effectiveness of treatments for medication-related osteonecrosis of the jaw: a systematic review and meta-analysis. J. Am. Dent. Assoc. 148, 584\u2013594 (2017).","journal-title":"J. Am. Dent. Assoc."},{"key":"75272_CR13","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/nrrheum.2011.181","volume":"8","author":"IR Reid","year":"2012","unstructured":"Reid, I. R. & Cornish, J. Epidemiology and pathogenesis of osteonecrosis of the jaw. Nat. Rev. Rheumatol. 8, 90\u201396 (2012).","journal-title":"Nat. Rev. Rheumatol."},{"key":"75272_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan, A. A. et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J. Bone Min. Res. 30, 3\u201323 (2015).","journal-title":"J. Bone Min. Res."},{"key":"75272_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto, S., Pautke, C., Van den Wyngaert, T., Niepel, D. & Schi\u00f8dt, M. Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat. Rev. 69, 177\u2013187 (2018).","journal-title":"Cancer Treat. Rev."},{"key":"75272_CR16","doi-asserted-by":"crossref","unstructured":"Russmueller, G. et al. The association of medication-related osteonecrosis of the jaw with Actinomyces spp. infection. Sci. Rep. 6, 1\u20138 (2016).","DOI":"10.1038\/srep31604"},{"key":"75272_CR17","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00784-018-2655-z","volume":"23","author":"M Zirk","year":"2019","unstructured":"Zirk, M. et al. Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw. Clin. Oral Investig. 23, 2143\u20132151 (2019).","journal-title":"Clin. Oral Investig."},{"key":"75272_CR18","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/j.1476-5381.2011.01592.x","volume":"165","author":"JWP Kuiper","year":"2012","unstructured":"Kuiper, J. W. P., Forster, C., Sun, C., Peel, S. & Glogauer, M. Zoledronate and pamidronate depress neutrophil functions and survival in mice. Br. J. Pharmacol. 165, 532\u2013539 (2012).","journal-title":"Br. J. Pharmacol."},{"key":"75272_CR19","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/j.it.2019.04.012","volume":"40","author":"C Silvestre-Roig","year":"2019","unstructured":"Silvestre-Roig, C., Fridlender, Z. G., Glogauer, M. & Scapini, P. Neutrophil diversity in health and disease. Trends Immunol. 40, 565\u2013583 (2019).","journal-title":"Trends Immunol."},{"key":"75272_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fphys.2018.00113","volume":"9","author":"C Rosales","year":"2018","unstructured":"Rosales, C. Neutrophil: A cell with many roles in inflammation or several cell types?. Front. Physiol. 9, 1\u201317 (2018).","journal-title":"Front. Physiol."},{"key":"75272_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1080\/21541248.2017.1304855","volume":"10","author":"B McCormick","year":"2019","unstructured":"McCormick, B., Chu, J. Y. & Vermeren, S. Cross-talk between Rho GTPases and PI3K in the neutrophil. Small GTPases 10, 187\u2013195 (2019).","journal-title":"Small GTPases"},{"key":"75272_CR22","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.bone.2010.11.008","volume":"49","author":"MJ Rogers","year":"2011","unstructured":"Rogers, M. J., Crockett, J. C., Coxon, F. P. & M\u00f6nkk\u00f6nen, J. Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49, 34\u201341 (2011).","journal-title":"Bone"},{"key":"75272_CR23","doi-asserted-by":"publisher","first-page":"1294","DOI":"10.1111\/odi.12908","volume":"24","author":"S Patntirapong","year":"2018","unstructured":"Patntirapong, S. & Poolgesorn, M. Alteration of macrophage viability, differentiation, and function by bisphosphonates. Oral Dis. 24, 1294\u20131302 (2018).","journal-title":"Oral Dis."},{"key":"75272_CR24","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1007\/s00784-015-1584-3","volume":"20","author":"S Hoefert","year":"2016","unstructured":"Hoefert, S. et al. Altered macrophagic THP-1 cell phagocytosis and migration in bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin. Oral Investig. 20, 1043\u20131054 (2016).","journal-title":"Clin. Oral Investig."},{"key":"75272_CR25","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1016\/j.jcms.2017.02.023","volume":"45","author":"F Wehrhan","year":"2017","unstructured":"Wehrhan, F. et al. Macrophage and osteoclast polarization in bisphosphonate associated necrosis and osteoradionecrosis. J. Cranio-Maxillofac. Surg. 45, 944\u2013953 (2017).","journal-title":"J. Cranio-Maxillofac. Surg."},{"key":"75272_CR26","doi-asserted-by":"crossref","unstructured":"Kalyan, S., Chandrasekaran, V., Quabius, E. S., Lindhorst, T. K. & Kabelitz, D. Neutrophil uptake of nitrogen-bisphosphonates leads to the suppression of human peripheral blood \u03b3\u03b4 T cells. Cell. Mol. Life Sci. 71, 2335\u20132346 (2014).","DOI":"10.1007\/s00018-013-1495-x"},{"key":"75272_CR27","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.4049\/jimmunol.170.11.5652","volume":"170","author":"M Glogauer","year":"2003","unstructured":"Glogauer, M. et al. Rac1 Deletion in mouse neutrophils has selective effects on neutrophil functions. J. Immunol. 170, 5652\u20135657 (2003).","journal-title":"J. Immunol."},{"key":"75272_CR28","doi-asserted-by":"publisher","first-page":"3758","DOI":"10.1182\/blood-2004-03-0781","volume":"104","author":"CX Sun","year":"2004","unstructured":"Sun, C. X. et al. Rac1 is the small GTPase responsible for regulating the neutrophil chemotaxis compass. Blood 104, 3758\u20133765 (2004).","journal-title":"Blood"},{"key":"75272_CR29","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ijom.2012.12.011","volume":"42","author":"CL Favot","year":"2013","unstructured":"Favot, C. L., Forster, C. & Glogauer, M. The effect of bisphosphonate therapy on neutrophil function: a potential biomarker. Int. J. Oral Maxillofac. Surg. 42, 619\u2013626 (2013).","journal-title":"Int. J. Oral Maxillofac. Surg."},{"key":"75272_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s00784-014-1219-0","volume":"19","author":"N Hagelauer","year":"2014","unstructured":"Hagelauer, N., Pabst, A. M., Ziebart, T., Ulbrich, H. & Walter, C. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes. Clin. Oral Investig. 19, 139\u2013148 (2014).","journal-title":"Clin. Oral Investig."},{"key":"75272_CR31","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3109\/10428194.2014.924117","volume":"56","author":"KM Sanfilippo","year":"2015","unstructured":"Sanfilippo, K. M. et al. Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk. Lymphoma 56, 615\u2013621 (2015).","journal-title":"Leuk. Lymphoma"},{"key":"75272_CR32","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1093\/annonc\/mdj105","volume":"17","author":"T Tanvetyanon","year":"2006","unstructured":"Tanvetyanon, T. & Stiff, P. J. Management of the adverse effects associated with intravenous bisphosphonates. Ann. Oncol. 17, 897\u2013907 (2006).","journal-title":"Ann. Oncol."},{"key":"75272_CR33","first-page":"1","volume":"12","author":"R Mhaskar","year":"2017","unstructured":"Mhaskar, R., Kumar, A., Miladinovic, B. & Djulbegovic, B. Bisphosphonates in multiple myeloma: an updated network meta-analysis. Cochrane Database Syst. Rev. 12, 1\u2013107 (2017).","journal-title":"Cochrane Database Syst. Rev."},{"key":"75272_CR34","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/bmt.2014.288","volume":"50","author":"N Areethamsirikul","year":"2015","unstructured":"Areethamsirikul, N. et al. CyBorD induction therapy in clinical practice. Bone Marrow Transplant. 50, 375\u2013379 (2015).","journal-title":"Bone Marrow Transplant."},{"key":"75272_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2019.02247","volume":"10","author":"A Aiello","year":"2019","unstructured":"Aiello, A. et al. Immunosenescence and its hallmarks: How to oppose aging strategically? A review of potential options for therapeutic intervention. Front. Immunol. 10, 1\u201319 (2019).","journal-title":"Front. Immunol."},{"key":"75272_CR36","doi-asserted-by":"crossref","unstructured":"S. Saffar, A., Ashdown, H. & S. Gounni, A. The molecular mechanisms of glucocorticoids-mediated neutrophil survival. Curr. Drug Targets 12, 556\u2013562 (2011).","DOI":"10.2174\/138945011794751555"},{"key":"75272_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00198-007-0540-8","volume":"19","author":"RGG Russell","year":"2008","unstructured":"Russell, R. G. G., Watts, N. B., Ebetino, F. H. & Rogers, M. J. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos. Int. 19, 733\u2013759 (2008).","journal-title":"Osteoporos. Int."},{"key":"75272_CR38","doi-asserted-by":"crossref","unstructured":"Moraschini, V., de Almeida, D. C. F., Figueredo, C. M. & Calasans-Maia, M. D. Association between biomarkers and medication-related osteonecrosis of the jaws: a systematic review. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 127, 504\u2013515 (2019).","DOI":"10.1016\/j.oooo.2019.02.014"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75272-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75272-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T17:12:08Z","timestamp":1670346728000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-75272-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,27]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["75272"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-75272-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,27]]},"assertion":[{"value":"28 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"18309"}}